+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer

Journal of Cancer Survivorship 8(2): 183-189

Cardiovascular disease is the leading noncancer cause of death among survivors of childhood cancer. Ejection fraction (EF) and fractional shortening (FS) are common echocardiographic measures of cardiac function, but newer imaging modalities may provide additional information about preclinical disease. This study aimed to evaluate these modalities in detection of anthracycline-induced cardiac toxicity. We compared mean radial displacement, EF, and FS among 17 adult survivors of childhood cancer exposed to ≥ 300 mg/m(2) of anthracyclines to 17 age- and sex-matched healthy controls. Survivors with a history of cardiac-directed radiation, diabetes, or heart disease were excluded. Survivors (35% male), mostly with history of treatment for a solid tumor, had a median age at diagnosis of 15 years (1-20) and 27 years (18-50) at evaluation. Median anthracycline exposure was 440 (range 300-645) mg/m(2). FS (35.5 vs. 39.6%, p < 0.01) and radial displacement (5.6 vs. 6.7 mm, p = 0.02) were significantly lower in survivors compared to controls, respectively. Although the mean EF was lower in survivors versus controls (55.4 vs. 59.7%), it was not statistically significant (p = 0.057). All echocardiographic measures were inversely associated with anthracycline dose, though radial displacement was no longer significantly correlated with anthracycline dose after controlling for survival time (p = 0.07), while EF remained correlated (p = 0.003). Radial displacement, EF, and FS are lower in childhood cancer survivors compared to controls. In this study, radial displacement added no new information beyond the traditional measures, but clinical utility remains undetermined and requires further longitudinal study.

(PDF emailed within 0-6 h: $19.90)

Accession: 053089193

Download citation: RISBibTeXText

PMID: 24317971

DOI: 10.1007/s11764-013-0326-2

Related references

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2015

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer. Rofo 176(9): 1245-1250, 2004

Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. Circulation. Cardiovascular Imaging 12(5): E008777, 2019

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST SUPPL ): 312, 1998

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2017

Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology 32(3): 342-353, 2011

Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4): 525-533, 2008

Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology 29(1): 103-112, 2014

The use of metabolic stress testing and exercise stress echocardiography in pediatric cancer survivors to detect early stages of late-onset anthracycline induced cardiotoxicity. Journal of Investigative Medicine 48(5): 235A, 2000

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatric Cardiology 36(6): 1112-1119, 2016

Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology 7(2): 122-128, 2007

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circulation. Cardiovascular Imaging 6(6): 873-880, 2014